Phase I study of DMP 840 in pediatric patients with refractory solid tumors

Investigational New Drugs

Volumn 16, Issue 1, 1998, Pages 45-49

  Thompson, Joyce ^a   Pratt, Charles B ^a,c   Stewart, Clinton F ^b   Avery, Loraine ^a   Bowman, Laura ^a   Zamboni, William C ^b   Pappo, Alberto ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

DMP 840; Pediatric tumors; Phase I study

Indexed keywords

ANTINEOPLASTIC AGENT; BISNAFIDE MESYLATE;

ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOLID TUMOR;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; ISOQUINOLINES; MESYLATES; NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031870995     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006014510078     Document Type: Article

References (15)

1. Braua MF, Castellano JM, Moran M, de Vega MJP, Ewing F, Qian X, Keilhauer G: Bis-naphthalimides, a novel class of antitumor agents. Proc Am Assoc Cancer Res 34:2285, 1993
2. Sun J-H, Behrens CH, Chen S-F, Kirshenbaum M, McRipley R, Gross JL: Synthesis and anti-proliferative properties of novel bis-naphthalimides, DMP 840 and its stereoisomers. Proc Am Assoc Cancer Res 34:2287, 1993
3. Behrens CH, Burns-Horwitz P, Dexter DL, Diamond M, Diamon R, Miller J, Page RJ, Sun J-H, Gross JL: Magnitude and duration of anti-tumor responses caused by DMP 840, a novel bis-naphthalimide anti-tumor agent against human solid tumor xenografts in vivo. Proc Am Assoc Cancer Res 34:2289, 1993
4. Bousquet PF, Conlon D, Braua M, Keihauer G, Romerdahl CA: Bis-naphthalimides demonstrate significant antitumor activity in vivo. Proc Am Assoc Cancer Res 34:2230, 1993
5. Houghton PJ, Cheshire P, Hallman JC, Gross JL, McRipley RJ, Sun JH, Behrens CH, Dexter DL, Houghton JA: Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile and pediatric cancer. Cancer Chemother Pharmacol 33:265-272, 1994
6. McRipley R, Behrens CH, Burns-Horwitz P, Czerniak P, Dexter DL, Diamond M, Diamond R, Miller J, Pate RJ, Sun J-H. Evaluation of DMP 840, a novel anti-tumor agent, in murine and human tumor models in vivo. Proc Am Assoc Cancer Res 34:2291, 1993
7. LoRosso PM, Deinchik L, Polin L, Jones J, Knight J, Behrens CH, Sun JH, McRipley R, Gross JL, Corbett TH: Antitumor activity of DMP 840. Proc Am Assoc Cancer Res 34:2265, 1993
8. Papp LM, Kirshenbaum MR, Chen SR, Stafford MM, Frederick JR, Behrens DL, Behrens CH, Sun JH, Gross JL: Mechanistic and anti-proliferative activities of DMP 840, a novel bis-naphthalimide anti-tumor agent. Proc Am Assoc Cancer Res 34:2288, 1993
9. Stafford MM, Kirshenbaum MR, Elliott KJ, Chen SF, Perrella F, Sun T, Trainor GL, Papp LM, Fredericks JR, Sun JH, Gross JL: DNA binding characteristics of DMP 840, a novel bis-naphthalimide anti-tumor agent. Proc Am Assoc Cancer Res 34:2292, 1993
10. Cobb P, Burris H, Drengler R, Fields S, Smith L, White L, Pieniaszek H, Gray J, Peterman V, Finizio M, Von Hoff D: Phase I trial of DMP 840 given as a 120 hour continuous infusion every 28 days. Proc Am Soc Clin Oncol 14:1577, 1995
11. O'Reilly S, Rowinsky EK, Grochow L, Adjel A, Bowling K, Slichenmyer W, Sartorius S, Finizio M, Gray PE, Pieniaszek H, Peterman VC, Mabring D, Donehower RC: Phase I and pharmacologic study of DMP 840 as a 24 hour infusion in patients with solid tumors. Proc Am Soc Clin Oncol 14:1529, 1995
12. Cobb P, Burris H, Finizio M, Lai C, Eckardt J, Fields S, Kuhn J, Nelson J, Bunitsky K, Pieniaszek H, Brogdon B, Van Hoff D: Phase I trial and pharmacokinetic study of a new bis-naphthalimide, DMP 840, given daily x 5. Proc Am Soc Clin Oncol 13:429, 1994
13. Maroun J, Stewart D, Goel R, Goss G, Verma S, Yan J, Finizio M, Lau CM, Bunitsky K, Pieniaszek H: Phase I pharmacokinetic study of DMP 840 given in a 3 weekly dosage in a 5 week schedule. Proc Am Soc Clin Oncol 13:400, 1994
14. Pratt CB, Rao BN, Stewart CF, Jenkins JJ: Successful treatment of metastatic choriocarcinoma after DMP 840. Urol Oncol 1:166-167, 1995
15. Slichenmeyer W, Finizio M, Sartorius S, Rowinsky E, Lai CM, Grochow L, Pieniaszek H, O'Reilly S, Bunitsky K, Brogdon B, Mabring D, Shifflett C, Donehower R: Phase I study of DMP 840 as a single infusion every three weeks. Proc Am Soc Clin Oncol 13:362, 1994